SCHEMBL23701421

SCHEMBL23701421

CS(=O)(=O)N1CCN(c2ccc(N3CC4CN(CCCC#N)CC4C3)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
EED O75530 1/20 0.41
GAA P10253 1/20 0.41
RORC P51449 5/20 0.41
POLB P06746 2/20 0.40
CTSC P53634 1/20 0.40
MEN1 O00255 3/20 0.39
MAPT P10636 3/20 0.39
KMT2A Q03164 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HTR7 P34969 2/20 0.39
TMEM97 Q5BJF2 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
USP30 Q70CQ3 1/20 0.38
RET P07949 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23701422 1.00 KDM4E (0.42) KDM4EEEDGAARORCPOLB
SCHEMBL27400154 0.85 KDM4E (0.54) KDM4EEEDGAARORCPOLB
SCHEMBL23701477 0.82 KDM4E (0.40) KDM4EGAARORCPOLBCTSC
SCHEMBL23701476 0.82 KDM4E (0.40) KDM4EGAARORCPOLBCTSC
SCHEMBL27399973 0.82 HTR7 (0.46) MEN1MAPTKMT2ASMN1; SMN2HTR7
SCHEMBL23701405 0.81 KDM4E (0.40) KDM4EGAARORCMAPTALDH1A1
SCHEMBL23701403 0.81 KDM4E (0.40) KDM4EGAARORCMAPTALDH1A1
SCHEMBL23701401 0.79 HRH3 (0.35) KDM4EGAAMEN1MAPTKMT2A
SCHEMBL23701487 0.77 ACACB (0.44) GAAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL23701485 0.77 ACACB (0.44) GAAMAPTSMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors LOX, LOXL1, LOXL3 KDM4E 685/4885EED 4552/4885GAA 867/4885
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS LOX, LOXL1, LOXL3 KDM4E 685/4885EED 4552/4885GAA 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.